REG - Eden Research plc - Mevalone Label Extension in France

Eden ResearchAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260107:nRSG8973Na&default-theme=true

RNS Number : 8973N  Eden Research plc  07 January 2026

As the information in this release pertains to EDEN RESEARCH PLC, this
announcement is deemed to constitute inside information as stipulated under
the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014
(the "UK MAR") which is part of UK law by virtue of the European Union
(Withdrawal) Act 2018. The information is disclosed in accordance with the
Company's obligations under Article 17 of the UK MAR. Upon the publication of
this announcement, this inside information is now considered to be in the
public domain.

 

7 January 2026

 

 

Eden Research Plc

("Eden" or "Company")

 

Mevalone Label Extension in France

 

Mevalone® approved in France for use on grapes against downy and powdery
mildew

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and
biocontrol technologies, is pleased to announce that Mevalone has been
granted approval by the French authorities for use on grapes to control downy
and powdery mildew, subject to customary restrictions.

 

France is one of the world's largest and most affected markets for grape downy
mildew, and this is driving steady demand for conventional fungicides,
biopesticides, and resistant varieties across its more-than 780,000 hectares
of vines. Climate‑driven increases in mildew pressure, regulatory pressure
on copper and synthetic chemistry, and growth in organic viticulture are
reshaping the structure and dynamics of this market.

 

Biopesticides are a fast‑growing segment of the French crop protection
market: the French biopesticides sector is estimated at more than USD 200
million in 2025 and is projected to grow strongly to 2030, with grapes
representing a key market segment because of heavy pressure from downy mildew,
powdery mildew and botrytis and the challenging regulatory restrictions placed
on pesticides in general.

 

Downy mildew has become one of the most damaging diseases in French vineyards
with recent years (2023-2024) seeing severe outbreaks in Bordeaux and many
other regions, cutting local harvests by up to a fifth or more.

 

While any estimate is subject to ever-evolving regulatory and commercial
circumstances, the Company currently estimates that the potential peak revenue
for this opportunity (with its current label extension conditions on the
timing of applications) to be in the region of up to €8 million per annum.
Given the timing of receipt of this label extension for two new diseases and
the industry's schedule for marketing and stocking products for the growing
season, the Company is not changing its market guidance at this stage but will
monitor this as the season develops.

 

 

Sean Smith, CEO of Eden Research, commented:

 

"With France recently having tightened rules on copper fungicides, revoking
approval for many formulations and leaving only a small number of authorised
copper products under stricter conditions, the approval of this label
extension for Mevalone is timely, creating a significant opportunity for Eden
in the coming years.

 

In addition, organic vineyard area has continued to increase with
approximately one-fifth of French vineyard land now farmed organically,
exceeding the national agricultural average and reinforcing demand for
alternative solutions such as Mevalone, which is already certified as
organic."

 

 

 

 

For further information contact:

 

 Eden Research plc                                                       www.edenresearch.com (http://www.edenresearch.com/)
 Sean Smith                                                              01285 359 555

Alex Abrey

 Cavendish Capital Markets Limited (Nominated advisor and joint broker)
 Giles Balleny / Elysia Bough (Corporate Finance)                        020 7220 0500

 Harriet Ward (Corporate Broking)

Dale Bellis (Sales)

 Oberon Capital (Joint Broker)                                           020 3179 5300
 Nick Lovering

 Mike Seabrook

 Adam Pollock

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                      eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle
crop destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

Follow Eden on LinkedIn (https://www.linkedin.com/company/eden-research-plc/)
, Twitter (https://twitter.com/edenresearch)  and YouTube
(https://www.youtube.com/@edenresearch580) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAUNRRRNAUARUR



            Copyright 2019 Regulatory News Service, all rights reserved